Friday broker round-up
13th Sep 2019 12:49
(Sharecast News) - Britvic: Jefferies upgrades to buy with a target price of 1000p.
Read moreWednesday broker round-up
11th Sep 2019 13:12
(Sharecast News) - Renew Holdings: Peel Hunt initiates at buy with a target price of 500p.
Read moreCiti reiterates 'buy' on AstraZeneca, says new drugs under-appreciated
11th Sep 2019 10:57
(Sharecast News) - Citi reiterated its 'buy' rating AstraZeneca on Wednesday, lifting the price target to 10,000p from 7,000 as it said the market continues to under-appreciate the commercial potential and operating leverage from drugs such as Tagrisso, Lynparza, roxadustat and Farxiga.
Read moreAstraZeneca's Imfinzi improves patient survival in lung cancer trial
9th Sep 2019 14:34
(Sharecast News) - AstraZeneca on Monday reported that its Imfinzi drug had improved overall survival by almost three months in patients with late-stage small cell lung cancer in a recent trial.
Read moreJP Morgan stays at 'overweight' on AstraZeneca, sees further re-rating ahead
5th Sep 2019 16:27
(Sharecast News) - Analysts at JP Morgan told clients to continue to overweight big market capitalisation stocks versus their smaller mid-cap peers over the next six months.
Read moreAstraZeneca receives Chinese marketing approval for Tagrisso
4th Sep 2019 08:20
(Sharecast News) - Biopharmaceutical giant AstraZeneca has received marketing authorisation for its lung cancer treatment Tagrisso from China's National Medical Products Administration.
Read moreMonday broker round-up
2nd Sep 2019 13:16
(Sharecast News) - Beazley: UBS upgrades to buy with a target price of 650p.
Read moreAstraZeneca reports 'positive' cardiovascular results from Brilinta and Farxiga drugs
2nd Sep 2019 07:41
(Sharecast News) - AstraZeneca on Monday reported a duo of "positive" results, including a trial that showed its cardiovascular drug, Brilinta, when combined with Aspirin, reduced the relative risk of heart attack or stroke by 10% when compared with aspirin alone.
Read moreAstraZeneca sees positive results from latest 'anifrolumab' trial
29th Aug 2019 07:29
(Sharecast News) - AstraZeneca announced on Thursday that the phase 3 'TULIP 2' trial for 'anifrolumab' - a potential new medicine for the treatment of systemic lupus erythematosus (SLE) - met its primary endpoint, achieving a statistically-significant and clinically-meaningful reduction in disease activity compared to placebo, with both arms receiving standard of care.
Read moreWednesday broker round-up
28th Aug 2019 12:43
(Sharecast News) - Greggs: UBS upgrades to buy with a target price of 2,300p.
Read moreAstraZeneca upbeat on progress with 'Fasenra' and 'Breztri Aerosphere'
28th Aug 2019 07:38
(Sharecast News) - AstraZeneca announced on Wednesday morning that the US Food and Drug Administration (FDA) has granted 'Orphan Drug Designation' to 'Fasenra' (benralizumab), for the treatment of eosinophilic oesophagitis (EoE).
Read moreAstraZeneca upbeat on progress with 'Fasenra' and 'Breztri Aerosphere'
28th Aug 2019 07:38
(Sharecast News) - AstraZeneca announced on Wednesday morning that the US Food and Drug Administration (FDA) has granted 'Orphan Drug Designation' to 'Fasenra' (benralizumab), for the treatment of eosinophilic oesophagitis (EoE).
Read moreAstraZeneca upbeat on progress with 'Fasenra' and 'Breztri Aerosphere'
28th Aug 2019 07:38
(Sharecast News) - AstraZeneca announced on Wednesday morning that the US Food and Drug Administration (FDA) has granted 'Orphan Drug Designation' to 'Fasenra' (benralizumab), for the treatment of eosinophilic oesophagitis (EoE).
Read moreAstraZeneca upbeat on progress with 'Fasenra' and 'Breztri Aerosphere'
28th Aug 2019 07:38
(Sharecast News) - AstraZeneca announced on Wednesday morning that the US Food and Drug Administration (FDA) has granted 'Orphan Drug Designation' to 'Fasenra' (benralizumab), for the treatment of eosinophilic oesophagitis (EoE).
Read moreAstraZeneca upbeat on progress with 'Fasenra' and 'Breztri Aerosphere'
28th Aug 2019 07:38
(Sharecast News) - AstraZeneca announced on Wednesday morning that the US Food and Drug Administration (FDA) has granted 'Orphan Drug Designation' to 'Fasenra' (benralizumab), for the treatment of eosinophilic oesophagitis (EoE).
Read more